Pulmonary Arterial Hypertension News and Research RSS Feed - Pulmonary Arterial Hypertension News and Research

Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Researchers call for earlier PAH diagnosis and treatment

Researchers call for earlier PAH diagnosis and treatment

A study has found that treatment of pulmonary arterial hypertension in patients younger than 55 years significantly improves their performance on the 6-minute walk test. [More]
Early decline in 6MWT distance predicts PAH worsening

Early decline in 6MWT distance predicts PAH worsening

Research shows that an early decline in 6-minute walk test distance can predict worsening of disease in patients with pulmonary arterial hypertension. [More]
Capillary pCO2 helps determine IPAH diagnosis

Capillary pCO2 helps determine IPAH diagnosis

Capillary pCO2 can be used to distinguish idiopathic pulmonary arterial hypertension from pulmonary hypertension due to heart failure with preserved ejection fraction, research indicates. [More]
Actavis seeks FDA marketing approval for Ambrisentan Tablets, 5 mg and 10 mg

Actavis seeks FDA marketing approval for Ambrisentan Tablets, 5 mg and 10 mg

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg. [More]
Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. [More]
Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma, Inc., a privatively held biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare diseases, announced today that its lead compound tacrolimus (SPI-026) has been granted Orphan Drug Designation by the U.S. Food & Drug Administration for the treatment of pulmonary arterial hypertension (PAH). [More]

Mechanistic subtypes of IPAH revealed

Researchers have provided evidence for distinct processes underlying vasodilator-responsive and nonresponsive idiopathic pulmonary arterial hypertension. [More]
Metabolic derangement may facilitate cell proliferation in PAH

Metabolic derangement may facilitate cell proliferation in PAH

An enzyme that facilitates modification of proteins via a glucose metabolism pathway may promote cell proliferation in the lung tissue of patients with idiopathic pulmonary arterial hypertension, say researchers. [More]

Prognostic potential for pericardial effusion in PAH patients

Monitoring pericardial effusion on serial transthoracic echocardiograms provides useful prognostic information in patients with pulmonary arterial hypertension, research suggests. [More]
PAH survival unaffected by rheumatoid arthritis origin

PAH survival unaffected by rheumatoid arthritis origin

Patients with rheumatoid arthritis-associated pulmonary arterial hypertension have comparable survival to those with idiopathic pulmonary arterial hypertension, researchers report. [More]
Radionuclide angiography-assessed RVEF predicts PAH outcomes

Radionuclide angiography-assessed RVEF predicts PAH outcomes

Baseline right ventricular ejection fraction as evaluated by conventional planar equilibrium radionuclide angiography is significantly associated with outcomes in patients with pulmonary arterial hypertension, research suggests. [More]

Mechanistic subtypes of IPAH revealed

Researchers have provided evidence for distinct processes underlying vasodilator-responsive and nonresponsive idiopathic pulmonary arterial hypertension. [More]
Concentric remodelling preserves right ventricular function in PAH

Concentric remodelling preserves right ventricular function in PAH

Systolic function is better preserved in patients with idiopathic pulmonary arterial hypertension if they have a higher right ventricle mass-to-volume ratio, research shows. [More]
Peripheral muscles weakened in PAH patients

Peripheral muscles weakened in PAH patients

Patients with pulmonary arterial hypertension have peripheral muscle weakness that is independent of impairments in their respiratory muscles, research shows. [More]
CT measures can refine PAH prognosis

CT measures can refine PAH prognosis

Structural features identifiable on computed tomography pulmonary angiography can provide prognostic information for patients with pulmonary arterial hypertension, say UK researchers. [More]
Ascendis Pharma initiates TransCon Treprostinil Phase 1 study in healthy volunteers

Ascendis Pharma initiates TransCon Treprostinil Phase 1 study in healthy volunteers

Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced that it has initiated a Phase 1 single ascending dose study of TransCon Treprostinil in healthy volunteers. [More]
Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV. [More]
United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

United Therapeutics Corporation (NASDAQ: UTHR) announced today that Medtronic, Inc. (NYSE: MDT) has submitted a pre-market approval application to the U.S. Food and Drug Administration (FDA) for the use of Medtronic's SynchroMed® II implantable drug infusion system (including a newly developed catheter) for use with United Therapeutics' Remodulin® (treprostinil) Injection delivered intravenously to patients with pulmonary arterial hypertension. [More]
PAH markers identified among Chinese systemic sclerosis patients

PAH markers identified among Chinese systemic sclerosis patients

A study of Chinese patients with systemic sclerosis has identified predictive markers for accompanying pulmonary arterial hypertension similar to those that have been identified in other ethnic groups. [More]
Cardiac monitoring foretells clinical deterioration in PAH

Cardiac monitoring foretells clinical deterioration in PAH

Monitoring right ventricular parameters can give advance warning of clinical deterioration in stable patients with idiopathic pulmonary arterial hypertension, research suggests. [More]
Advertisement
Advertisement